AstraZeneca says to invest $50 bn in the US / Photo: Jonathan NACKSTRAND - AFP/File
-
Kenya's economy faces climate change risks: World Bank
-
Norway crown princess likely to undergo lung transplant
-
France's budget hits snag in setback for embattled PM
-
Volatile Oracle shares a proxy for Wall Street's AI jitters
-
Japan hikes interest rates to 30-year-high
-
Brazil's top court strikes down law blocking Indigenous land claims
-
'We are ghosts': Britain's migrant night workers
-
Asian markets rise as US inflation eases, Micron soothes tech fears
-
Trump signs $900 bn defense policy bill into law
-
EU-Mercosur deal delayed as farmers stage Brussels show of force
-
Harrison Ford to get lifetime acting award
-
Trump health chief seeks to bar trans youth from gender-affirming care
-
Argentine unions in the street over Milei labor reforms
-
Brazil open to EU-Mercosur deal delay as farmers protest in Brussels
-
Brussels farmer protest turns ugly as EU-Mercosur deal teeters
-
US accuses S. Africa of harassing US officials working with Afrikaners
-
ECB holds rates as Lagarde stresses heightened uncertainty
-
Trump Media announces merger with fusion power company
-
Stocks rise as US inflation cools, tech stocks bounce
-
Zelensky presses EU to tap Russian assets at crunch summit
-
Danish 'ghetto' residents upbeat after EU court ruling
-
ECB holds rates but debate swirls over future
-
Bank of England cuts interest rate after UK inflation slides
-
Have Iran's authorities given up on the mandatory hijab?
-
British energy giant BP extends shakeup with new CEO pick
-
EU kicks off crunch summit on Russian asset plan for Ukraine
-
Sri Lanka plans $1.6 bn in cyclone recovery spending in 2026
-
Most Asian markets track Wall St lower as AI fears mount
-
Danish 'ghetto' tenants hope for EU discrimination win
-
What to know about the EU-Mercosur deal
-
Trump vows economic boom, blames Biden in address to nation
-
ECB set to hold rates but debate swirls over future
-
EU holds crunch summit on Russian asset plan for Ukraine
-
Nasdaq tumbles on renewed angst over AI building boom
-
Billionaire Trump nominee confirmed to lead NASA amid Moon race
-
CNN's future unclear as Trump applies pressure
-
German MPs approve 50 bn euros in military purchases
-
EU's Mercosur trade deal hits French, Italian roadblock
-
Warner Bros rejects Paramount bid, sticks with Netflix
-
Crude prices surge after Trump orders Venezuela oil blockade
-
Warner Bros. Discovery rejects Paramount bid
-
Doctors in England go on strike for 14th time
-
Ghana's Highlife finds its rhythm on UNESCO world stage
-
Stocks gain as traders bet on interest rate moves
-
France probes 'foreign interference' after malware found on ferry
-
Europe's Ariane 6 rocket puts EU navigation satellites in orbit
-
Bleak end to the year as German business morale drops
-
Hundreds queue at Louvre museum as strike vote delays opening
-
Markets rise even as US jobs data fail to boost rate cut bets
-
Asian markets mixed as US jobs data fails to boost rate cut hopes
AstraZeneca says to invest $50 bn in the US
British pharmaceutical giant AstraZeneca said Tuesday it would invest $50 billion in the United States amid a looming deadline of ramped-up tariffs from Washington.
A large chunk of the funds will go toward building a multi-billion-dollar manufacturing centre in Virginia, the company said in a statement, adding that it expects 50 percent of its revenue to come from the United States by 2030.
"Today’s announcement underpins our belief in America’s innovation in biopharmaceuticals," the statement quoted CEO Pascal Soriot as saying.
US President Donald Trump has opened the door to potential tariffs targeting pharmaceuticals, which have so far benefited from exemptions to his sweeping levies on imports from trading partners.
He ordered an investigation launched into pharmaceutical imports, suggesting that levies could reach up to 200 percent.
The United States is a key market for the pharmaceutical industry, and AstraZeneca had already announced in April that it had begun transferring part of its European production to the United States.
"For decades Americans have been reliant on foreign supply of key pharmaceutical products," US Commerce Secretary Howard Lutnick said in a statement.
He added that the new tariffs are focused on "ending this structural weakness".
The announcement included a new factory in Virginia, which will be the company's "largest single manufacturing investment".
Other major pharmaceutical companies, which had been exempt from tariffs for 30 years, have, in recent months, begun shifting investment and production to the United States.
D.Philippon--CPN